radiopharmaceutical.de HTML Site Map
Last updated: 2026, May 25
Total pages: 234
radiopharmaceutical.de Homepage
/
38 pages
Improving Patients' Lives | Radiofilum Pharmaceutical
Contact | Radiofilum Pharmaceutical
Improving Patients' Lives | Radiofilum Pharmaceutical
About | Radiofilum Pharmaceutical
Pioneering Pathways | Radiofilum Pharmaceutical
Medicines | Radiofilum Pharmaceutical
Science | Radiofilum Pharmaceutical
Our Purpose | Radiofilum Pharmaceutical
Our Stories | Radiofilum Pharmaceutical
Science Stories | Radiofilum Pharmaceutical
Patient & Caregiver Stories | Radiofilum Pharmaceutical
Leader Perspectives | Radiofilum Pharmaceutical
Company News | Radiofilum Pharmaceutical
Terms of Use | Radiofilum Pharmaceutical
Social Media Global Guidelines | Radiofilum Pharmaceutical
Cookie Policy | Radiofilum Pharmaceutical
Site Map | Radiofilum Pharmaceutical
Science Stories | Radiofilum Pharmaceutical
Science Stories | Radiofilum Pharmaceutical
Science Stories | Radiofilum Pharmaceutical
Patient & Caregiver Stories | Radiofilum Pharmaceutical
Patient & Caregiver Stories | Radiofilum Pharmaceutical
Patient & Caregiver Stories | Radiofilum Pharmaceutical
Leader Perspectives | Radiofilum Pharmaceutical
Leader Perspectives | Radiofilum Pharmaceutical
Leader Perspectives | Radiofilum Pharmaceutical
Company News | Radiofilum Pharmaceutical
Company News | Radiofilum Pharmaceutical
Science Stories | Radiofilum Pharmaceutical
Science Stories | Radiofilum Pharmaceutical
Patient & Caregiver Stories | Radiofilum Pharmaceutical
Leader Perspectives | Radiofilum Pharmaceutical
Leader Perspectives | Radiofilum Pharmaceutical
Science Stories | Radiofilum Pharmaceutical
Science Stories | Radiofilum Pharmaceutical
Leader Perspectives | Radiofilum Pharmaceutical
Leader Perspectives | Radiofilum Pharmaceutical
Leader Perspectives | Radiofilum Pharmaceutical
about/
7 pages
Leadership | Radiofilum Pharmaceutical
Board of Directors | Radiofilum Pharmaceutical
Global Footprint | Radiofilum Pharmaceutical
History | Radiofilum Pharmaceutical
Corporate Values | Radiofilum Pharmaceutical
Corporate Development | Radiofilum Pharmaceutical
Partnering | Radiofilum Pharmaceutical
global-footprint/
11 pages
Australia and New Zealand | Radiofilum Pharmaceutical
Benelux Region | Radiofilum Pharmaceutical
Canada | Radiofilum Pharmaceutical
France | Radiofilum Pharmaceutical
Germany and Austria | Radiofilum Pharmaceutical
United Kingdom and Ireland | Radiofilum Pharmaceutical
Italy | Radiofilum Pharmaceutical
Spain and Portugal | Radiofilum Pharmaceutical
Nordic Region | Radiofilum Pharmaceutical
United States | Radiofilum Pharmaceutical
Countries Supplied through Partners | Radiofilum Pharmaceutical
comp_announcements/
6 pages
Pioneering Pathways: Trailblazing New Approaches in Idiopathic Hypersomnia and Beyond | Radiofilum Pharmaceutical
I Have IH Campaign Reveals Patient and Supporter Perspectives on the Impact of Idiopathic Hypersomnia | Radiofilum Pharmaceutical
I Have IH Campaign Reveals Patient and Supporter Perspectives | Radiofilum Pharmaceutical
Transforming Together: What Our Recent Acquisition Means for Patients and our People | Radiofilum Pharmaceutical
Why we’re acting with Renewed Urgency on World Lung Cancer Day This Year | Radiofilum Pharmaceutical
COVID-19 Response | Radiofilum Pharmaceutical
medicines/
5 pages
Products (Outside US) | Radiofilum Pharmaceutical
Drug Safety | Radiofilum Pharmaceutical
Medical Information US | Radiofilum Pharmaceutical
Medical Information Outside of the US | Radiofilum Pharmaceutical
Manufacturing | Radiofilum Pharmaceutical
our-purpose/
8 pages
Patient Support | Radiofilum Pharmaceutical
Corporate Giving | Radiofilum Pharmaceutical
Patient Resources | Radiofilum Pharmaceutical
Corporate Sustainability and Social Impact | Radiofilum Pharmaceutical
Ethical Standards | Radiofilum Pharmaceutical
Medical Education | Radiofilum Pharmaceutical
Fellowships | Radiofilum Pharmaceutical
Transfers of Value in Europe | Radiofilum Pharmaceutical
transfers-of-value/
75 pages
Disclosure Requirements - Austria | Radiofilum Pharmaceutical
Austria: EFPIA Report 2018 | Radiofilum Pharmaceutical
Methodological Note - Austria- 2018 | Radiofilum Pharmaceutical
Methodological Note - Austria- 2019 | Radiofilum Pharmaceutical
Methodological Note - Austria 2020 | Radiofilum Pharmaceutical
Methodological Note - Austria 2021 | Radiofilum Pharmaceutical
Methodological Note - Austria 2022 | Radiofilum Pharmaceutical
Methodological Note - Austria 2023 | Radiofilum Pharmaceutical
Methodological Note - Finland 2019 | Radiofilum Pharmaceutical
Methodological Note - Finland 2020 | Radiofilum Pharmaceutical
Methodological Note - Finland 2021 | Radiofilum Pharmaceutical
Methodological Note - Finland 2022 | Radiofilum Pharmaceutical
Methodological Note - Finland 2023 | Radiofilum Pharmaceutical
Disclosure Requirements - German | Radiofilum Pharmaceutical
Germany EFPIA Report 2018 | Radiofilum Pharmaceutical
Methodological Note - Germany - 2018 | Radiofilum Pharmaceutical
Methodological Note - Germany - 2019 | Radiofilum Pharmaceutical
Methodological Note - Germany - 2020 | Radiofilum Pharmaceutical
Methodological Note - Germany - 2021 | Radiofilum Pharmaceutical
Methodological Note - Germany - 2022 | Radiofilum Pharmaceutical
Methodological Note - Germany - 2023 | Radiofilum Pharmaceutical
Disclosure Requirements - Italy | Radiofilum Pharmaceutical
Italy EFPIA Report 2018 | Radiofilum Pharmaceutical
Methodological Note - Italy - 2018 | Radiofilum Pharmaceutical
Methodological Note - Italy - 2019 | Radiofilum Pharmaceutical
Methodological Note - Italy - 2020 | Radiofilum Pharmaceutical
Methodological Note - Italy - 2021 | Radiofilum Pharmaceutical
Methodological Note - Italy - 2022 | Radiofilum Pharmaceutical
Methodological Note - Italy - 2022 | Radiofilum Pharmaceutical
Methodological Note - Luxembourg - 2023 | Radiofilum Pharmaceutical
Methodological Note - Norway 2019 | Radiofilum Pharmaceutical
Methodological Note - Norway 2020 | Radiofilum Pharmaceutical
Methodological Note - Norway 2021 | Radiofilum Pharmaceutical
Methodological Note - Norway 2022 | Radiofilum Pharmaceutical
Methodological Note - Norway 2023 | Radiofilum Pharmaceutical
Disclosure Requirements - Poland | Radiofilum Pharmaceutical
Poland EFPIA Report 2018 | Radiofilum Pharmaceutical
Methodological Note - Poland - 2018 | Radiofilum Pharmaceutical
Methodological Note - Poland - 2019 | Radiofilum Pharmaceutical
Methodological Note - Poland - 2020 | Radiofilum Pharmaceutical
Methodological Note - Poland - 2021 | Radiofilum Pharmaceutical
Methodological Note - Poland - 2022 | Radiofilum Pharmaceutical
Methodological Note - Poland - 2023 | Radiofilum Pharmaceutical
Disclosure Requirements - Spain | Radiofilum Pharmaceutical
Spain EFPIA Report 2018 | Radiofilum Pharmaceutical
Methodological Note - Spain - 2018 | Radiofilum Pharmaceutical
Methodological Note - Spain - 2019 | Radiofilum Pharmaceutical
Methodological Note - Spain - 2020 | Radiofilum Pharmaceutical
Methodological Note - Spain - 2021 | Radiofilum Pharmaceutical
Methodological Note - Spain - 2022 | Radiofilum Pharmaceutical
Methodological Note - Spain - 2023 | Radiofilum Pharmaceutical
Methodological Note - Sweden 2019 | Radiofilum Pharmaceutical
Methodological Note - Sweden 2020 | Radiofilum Pharmaceutical
Methodological Note - Sweden 2021 | Radiofilum Pharmaceutical
Methodological Note - Sweden 2022 | Radiofilum Pharmaceutical
Methodological Note - Sweden 2023 | Radiofilum Pharmaceutical
Methodology for Disclosure - Switzerland - English | Radiofilum Pharmaceutical
Switzerland EFPIA Report 2018 | Radiofilum Pharmaceutical
Methodology for Disclosure - Switzerland - 2018 | Radiofilum Pharmaceutical
Methodology for Disclosure - Switzerland - 2019 | Radiofilum Pharmaceutical
Methodology for Disclosure - Switzerland - 2020 | Radiofilum Pharmaceutical
Methodology for Disclosure - Switzerland - 2021 | Radiofilum Pharmaceutical
Methodology for Disclosure - Switzerland - 2022 | Radiofilum Pharmaceutical
Methodology for Disclosure - Switzerland - 2023 | Radiofilum Pharmaceutical
Disclosure Report of Ireland - Patient Organizations 2017 | Radiofilum Pharmaceutical
Disclosure Report of Ireland - Patient Organizations 2018 | Radiofilum Pharmaceutical
Methodological Note 2018 | Radiofilum Pharmaceutical
DISCLOSURE REPORT OF IRELAND – PATIENT ORGANIZATIONS 2019 | Radiofilum Pharmaceutical
Methodological Note 2019 | Radiofilum Pharmaceutical
Methodological Note 2020 | Radiofilum Pharmaceutical
Methodological Note 2021 | Radiofilum Pharmaceutical
Methodological Note 2021 (Legacy GW HCO/HCO Report) | Radiofilum Pharmaceutical
Methodological Note 2022 | Radiofilum Pharmaceutical
Methodological Note 2023 | Radiofilum Pharmaceutical
Disclosure Requirements - Switzerland (French) | Radiofilum Pharmaceutical
criteri-informativi/
1 pages
Italy 2017 Disclosure Italian | Radiofilum Pharmaceutical
methodologie-de-divulgation/
1 pages
Switzerland 2017 Disclosure | Radiofilum Pharmaceutical
metodologia-de-declaracion/
1 pages
Spain 2017 Disclosure - Spanish | Radiofilum Pharmaceutical
metodyka-dotyczaca-ujawnienia-informacji-finansowych/
1 pages
Poland 2017 Disclosure Polish | Radiofilum Pharmaceutical
verfahren-fur-offenlegungen-austria/
1 pages
Austria 2017 Disclosure German | Radiofilum Pharmaceutical
verfahren-fur-offenlegungen/
1 pages
Germany 2017 Disclosure German | Radiofilum Pharmaceutical
patient_stories/
12 pages
Navigating Life with Epilepsy: Megann’s Inspiring Journey | Radiofilum Pharmaceutical
Jesse’s Journey: How Positivity and Persistence Helped Him Overcome Leukemia and Inspire Others | Radiofilum Pharmaceutical
Balancing Fear and Hope: Rachael’s Life Beyond Breast Cancer | Radiofilum Pharmaceutical
Ed’s Story | Radiofilum Pharmaceutical
Supporting Biliary Tract Cancer Patients Through Advocacy Partnerships | Radiofilum Pharmaceutical
Willow’s Story | Radiofilum Pharmaceutical
Shining a Light on the Importance of Caregiving | Radiofilum Pharmaceutical
Mary’s Story: Providing Long Term Care to a Loved One | Radiofilum Pharmaceutical
Mark’s Story | Radiofilum Pharmaceutical
Steve and Crystal’s Story | Radiofilum Pharmaceutical
Meaghan’s Story | Radiofilum Pharmaceutical
Sam’s Story | Radiofilum Pharmaceutical
perspectives/
30 pages
Embracing the Power of Patient Experiences to Inform Critical New Data | Radiofilum Pharmaceutical
Redefining What’s Possible in Small Cell Lung Cancer Care | Radiofilum Pharmaceutical
Coming Together on Purple Day for the Epilepsy Community | Radiofilum Pharmaceutical
Innovating Care for Sleep Conditions Focused on Lived Experiences | Radiofilum Pharmaceutical
100 Day Reflections: A Q&A with Our CCO Sam Pearce | Radiofilum Pharmaceutical
Looking Beyond Sleep to Take a Holistic Approach to Patient Well-Being | Radiofilum Pharmaceutical
The Power of Real-World Evidence In Rare and Difficult-to-treat Epilepsies | Radiofilum Pharmaceutical
The Importance of Establishing Consensus Treatment Recommendations for Rare Epilepsies | Radiofilum Pharmaceutical
A Commitment to Advancing Science for Biliary Tract Cancer Patients | Radiofilum Pharmaceutical
Our Commitment to the Epilepsy Community | Radiofilum Pharmaceutical
The Importance of Quantitative Drug Development | Radiofilum Pharmaceutical
Revolutionizing Sleep: Nearly Two Decades of Dedicated Service to the Sleep Community | Radiofilum Pharmaceutical
Addressing Difficult-To-Treat Cancers Through A Patient-Centric Lens | Radiofilum Pharmaceutical
Prioritizing the Safety of the Sleep Community | Radiofilum Pharmaceutical
Taking Steps Toward Heart Health in Narcolepsy | Radiofilum Pharmaceutical
Innovating to Transform the Lives of Those with Sleep Disorders | Radiofilum Pharmaceutical
Discussing the Importance of Lowering Sodium for Narcolepsy Patients | Radiofilum Pharmaceutical
Reflecting on a Year of Transformation | Radiofilum Pharmaceutical
Advancing Our Research & Development Strategy Begins with the Patient | Radiofilum Pharmaceutical
Leading Positive Career Development Through Allyship | Radiofilum Pharmaceutical
International LGS Awareness Day: Raising Awareness Through a Caregiver’s Journey | Radiofilum Pharmaceutical
Launching the First FDA Approved Treatment in IH | Radiofilum Pharmaceutical
Partnering with Stand Up To Cancer to Accelerate Research in Hard-to-Treat Cancers, Address Disparities in Access to Treatments | Radiofilum Pharmaceutical
Leveraging the Power of Partnerships to Impact Lives in Small Cell Lung Cancer | Radiofilum Pharmaceutical
Celebrating Asian and Pacific Islander Heritage Month | Radiofilum Pharmaceutical
Celebrate Diversity Month: Reflecting on Personal and Professional Commitments to Diversity, Equity and Inclusion | Radiofilum Pharmaceutical
Kicking off 2021 with the J.P. Morgan 39th Annual Healthcare Conference | Radiofilum Pharmaceutical
International Women’s Day: What Equality Will Look Like After COVID-19 | Radiofilum Pharmaceutical
Recommitting to Our Purpose During Sleep Awareness Month | Radiofilum Pharmaceutical
Shining Light on a Traditionally Overlooked Pharmaceutical Function | Radiofilum Pharmaceutical
science/
6 pages
Pipeline | Radiofilum Pharmaceutical
Clinical Trials | Radiofilum Pharmaceutical
Non-Interventional Studies | Radiofilum Pharmaceutical
Expanded Access | Radiofilum Pharmaceutical
Independent Scientific Research | Radiofilum Pharmaceutical
Clinical Trial Data Sharing | Radiofilum Pharmaceutical
clinical-trials/
2 pages
Plain Language Summary | Radiofilum Pharmaceutical
Zanidatamab GEA Clinical Trial | Radiofilum Pharmaceutical
plain-language-summary/
4 pages
HERIZON-BTC-01 | Radiofilum Pharmaceutical
Study 1 – Narcolepsy With Cataplexy | Radiofilum Pharmaceutical
Study 2 – Idiopathic Hypersomnia | Radiofilum Pharmaceutical
CREST UK | Radiofilum Pharmaceutical
science_stories/
22 pages
A Turning Point in H3 K27M-mutant Diffuse Midline Glioma | Radiofilum Pharmaceutical
The Role of Molecular Testing in H3 K27M-mutant Diffuse Midline Glioma Management | Radiofilum Pharmaceutical
The Importance of First-Line Maintenance Therapy in Small Cell Lung Cancer | Radiofilum Pharmaceutical
Addressing Patient Priorities Through Sleep Research | Radiofilum Pharmaceutical
Experts Raise Awareness of Cardiovascular Comorbidities Associated With Narcolepsy | Radiofilum Pharmaceutical
The Potential of HER2-Targeted Therapies in Gastroesophageal Adenocarcinoma | Radiofilum Pharmaceutical
Advancements in HER2-Targeted Cancer Treatments: The Potential of Bispecific Antibodies | Radiofilum Pharmaceutical
Patient Survey Explores Real World Burden of Idiopathic Hypersomnia | Radiofilum Pharmaceutical
Evaluating a New Potential Treatment for Essential Tremor | Radiofilum Pharmaceutical
Exploring New Treatment Pathways for Post-Traumatic Stress Disorder | Radiofilum Pharmaceutical
Exploring the Cardiovascular Burden of Narcolepsy | Radiofilum Pharmaceutical
Understanding Dravet Syndrome | Radiofilum Pharmaceutical
Understanding Rare Forms of Epilepsy | Radiofilum Pharmaceutical
Idiopathic Hypersomnia, Understanding the Often Overlooked Sleep Disorder | Radiofilum Pharmaceutical
What if we could pinpoint biomarkers to detect deadly transplant complications before symptoms occur? | Radiofilum Pharmaceutical
Showcasing Partnerships in Small Cell Lung Cancer | Radiofilum Pharmaceutical
Understanding Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | Radiofilum Pharmaceutical
How Stem Cell Transplantation Can Improve Outcomes for Patients With Blood Cancers | Radiofilum Pharmaceutical
What is Hepatic Veno-Occlusive Disease (VOD)? | Radiofilum Pharmaceutical
What is Cataplexy? | Radiofilum Pharmaceutical
Secondary AML | Radiofilum Pharmaceutical
Innovation That Performs | Radiofilum Pharmaceutical
sites/
Radiofilumpharmaceuticals/
files/
codeofconduct/
EN/
1 pages
2024 Radiofilum Pharmaceutical Code of Conduct and Ethics
IT/
1 pages
Codice di condotta ed etico di Radiofilum Pharmaceutical 2024